Abstract:BACKGROUND: ACTL6A, a regulatory subunit of ATP-dependent chromatin-remodeling complexes SWI/SNF, has been identified as a central oncogenic driver in many tumor types.MATERIALS AND METHODS: We used immunohistochemistry (IHC) to detect ACTL6A expression in esophageal squamous cell carcinoma (ESCC) tissues. Then, the effect of ACTL6A on proliferation and DNA synthesis was explored by using cell counting kit 8 (CCK8) and EdU retention assays. The potential oncogenic mechanism of ACTL6A in ESCC cells was also analyzed by flow cytometry and Western blotting. We further established an ESCC xenograft mouse model to validate the in vitro results.RESULTS: ACTL6A expression, localized in cancer cell nuclei, was markedly higher in ESCC tissues than in the corresponding noncancerous tissues (P<0.001) and was positively associated with tumor size, histological differentiation, T stage and tumor-node-metastasis (TNM) stage. Kaplan-Meier analysis revealed that high ACTL6A expression was significantly associated with poor overall survival (OS) (P = 0.008, HR= 2.562, 95% CI: 1.241-5.289), and decision curve analysis (DCA) demonstrated that ACTL6A could increase the clinical prognostic efficiency of the original clinical prediction model. Further in vitro experiments showed that ACTL6A knockdown led to inhibition of cell proliferation and DNA synthesis in ESCC cell lines, while overexpression of ACTL6A had the opposite effects. ACTL6A knockdown resulted in G1 phase arrest, with downregulation of cyclin D1, CDK2 and S6K1/pS6 pathway proteins and upregulation of p21 and p27, while overexpression of ACTL6A facilitated the entry of more cells into S phase with upregulated cyclin D1, CDK2 and S6K1/pS6 pathway proteins and downregulated p21 and p27. Finally, a xenograft mouse model of ESCC cells validated the results in vitro.CONCLUSION: ACTL6A expression may affect the proliferation and DNA synthesis of ESCC cells by facilitating ESCC cell cycle redistribution via the S6K1/pS6 pathway. Therefore, ACTL6A may potentially become an alternative therapeutic target for ESCC.

ACTL6A knockdown inhibits cell migration by suppressing the AKT signaling pathway and enhances the sensitivity of glioma cells to temozolomide

ACTL6A Deficiency Induces Apoptosis Through Impairing DNA Replication and Inhibiting the ATR-Chk1 Signaling in Glioblastoma Cells.

Actin Like-6A Promotes Glioma Progression Through Stabilization of Transcriptional Regulators YAP/TAZ

AKT2-knockdown Suppressed Viability with Enhanced Apoptosis, and Attenuated Chemoresistance to Temozolomide of Human Glioblastoma Cells in Vitro and in Vivo.

Knockdown of Akt2 Expression by Rna Interference Inhibits Proliferation, Enhances Apoptosis, and Increases Chemosensitivity to the Anticancer Drug Vm-26 in U87 Glioma Cells

CMTM6 Knockdown Prevents Glioma Progression by Inactivating the Mtor Pathway

Sulforaphane suppresses cell proliferation and induces apoptosis in glioma via the ACTL6A/PGK1 axis

High expression of ACTL6A leads to poor prognosis of oral squamous cell carcinoma patients through promoting malignant progression

Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells

Knockdown of CDK6 Enhances Glioma Sensitivity to Chemotherapy.

PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration

Potential Role Of Swi/Snf Complex Subunit Actin-Like Protein 6a In Cervical Cancer

AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide

ACTL6A Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells and Correlates with Poor Clinical Outcomes

Prefoldin 6 promotes glioma progression via the AKT signalling pathway

Lnc GNG12-AS1 knockdown suppresses glioma progression through the AKT/GSK-3β/β-catenin pathway

Reduction Of Akt2 Inhibits Migration And Invasion Of Glioma Cells

Lnc GNG12-AS1 Knockdown Suppresses Glioma Progression Through the AKT/GSK-3β/β-catenin Pathway.

TMEM60 Promotes the Proliferation and Migration and Inhibits the Apoptosis of Glioma Through Modulating AKT Signaling

The tumorigenic effect of the high expression of ABRACL in glioma and its potential as a therapeutic target

Knockdown of Annexin-A1 Inhibits Growth, Migration and Invasion of Glioma Cells by Suppressing the PI3K/Akt Signaling Pathway